Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowel Disease

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Sep 4, 2025--

Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. Proceeds will advance BOOM-IBD2, the first pivotal trial of implantable neuromodulation in inflammatory bowel disease, with an initial focus on ulcerative colitis. The trial is currently enrolling patients at leading medical centers across the U.S. (NCT06571669).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250904154790/en/

Ulcerative colitis, the most common form of IBD, is a chronic autoimmune disease affecting millions of people in the U.S. and Europe, and there are no device-based options in this field. Boomerang is evaluating whether a small implanted device that delivers gentle nerve stimulation, known as sacral neuromodulation, can help address symptom burden in ulcerative colitis. The company completed a 40-patient feasibility study in Crohn's disease and ulcerative colitis, and those results informed the design of BOOM-IBD2, its pivotal trial in ulcerative colitis. Sacral neuromodulation itself has a long safety record in other conditions, with more than 500,000 procedures performed worldwide.

"Ulcerative colitis patients struggle with symptoms that profoundly affect their daily lives," said Heather Simonsen, CEO of Boomerang Medical. "Our pivotal trial asks a simple but critical question: can this therapy meaningfully reduce symptom burden and improve quality of life for people living with ulcerative colitis? With the continued support of our investors, we're pursuing that answer for patients and their physicians."

"There is a clear and significant unmet need for new approaches to help patients suffering from the debilitating symptoms of ulcerative colitis," said Tom Shehab, MD, gastroenterologist, Managing Partner at Arboretum Ventures and member of the Board of Directors. "We are impressed with the Boomerang team and their rigorous approach to clinical development. We are confident this financing will position them well to complete their pivotal trial and move this promising therapy forward."

The Crohn's & Colitis Foundation named Boomerang Medical its "Emerging Leader in IBD"—the first medical device company to receive this recognition.

For more information about BOOM-IBD2 or to refer patients, physicians can visit ClinicalTrials.gov: NCT06571669.

About Boomerang Medical Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. Headquartered on the campus of El Camino Hospital in Mountain View, California, the company is a Company-In-Residence at Fogarty Innovation, the only healthcare-focused incubator of its kind in the U.S. Boomerang was the first medical device company recognized as "Emerging Leader in IBD" by the Crohn's & Colitis Foundation. For more information, visit www.boomerangmedical.com.

About Arboretum Ventures Founded in 2002, Arboretum Ventures manages over $1 billion in healthcare venture capital from its Ann Arbor, Michigan base. The firm focuses on medical devices and healthcare services that address significant unmet needs. Portfolio companies have achieved multiple strategic exits to industry leaders. Visit www.arboretumvc.com.

About Hatteras Venture Partners Founded in 2000, Hatteras Venture Partners has invested in over 100 healthcare companies from its Research Triangle Park, North Carolina headquarters. The firm recently raised over $200 million across two healthcare-focused funds. Visit www.hatterasvp.com.

Heather Simonsen, CEO, Boomerang Medical

ISLAMABAD (AP) — Pakistan’s military pushed back Friday after imprisoned former Prime Minister Imran Khan called the country’s army chief “mentally unstable.” The army labeled Khan “mentally ill” and accused him of using family visits and social media posts to attack the armed forces and sow division.

Army spokesperson Lt. Gen. Ahmed Sharif Chaudhry, without directly naming Khan, described him as a “narcissist” whose political ambitions had grown so extreme that he believed “if I am not in power, nothing else should exist.”

Chaudhry told a televised news conference that people meeting Khan in prison were being used “to spread poison against the army.” His remarks came after one of Khan's sisters met with him at a prison, and said her brother was angry at army chief Gen. Asim Munir.

Chaudhry's rare remarks also followed a post by Khan on X a day earlier in which he labeled Munir a “mentally unstable person” and accused him of moral decline that had caused “the complete collapse of the Constitution and rule of law in Pakistan.” Khan said he and his wife were jailed on fabricated charges “at his command” and claimed he was being held in solitary confinement and subjected to psychological pressure.

Khan’s spokesperson, Zulfiquar Bukhari, said the army’s news conference was driven by anger, not reason, and included blatant threats against Khan and his PTI party. In a statement, he called it a clear attempt to pave the way for a harsher crackdown on the party and worsen the mental torture and his conditions in jail.

“They have already banned meetings with him going forward,” he said.

Khan, 73, has been imprisoned since 2023 following a corruption conviction and faces a series of other charges.

Chaudhry, at the news conference, displayed Khan’s latest post on X, saying Afghan and Indian media had amplified the “nonsense” of a “mentally ill person” and his allegations against Munir were baseless.

The latest development came a day after Pakistan's President Asif Ali Zardari and Prime Minister Shehbaz Sharifapproved the promotion of the widely popular Munir as the chief of defense forces, a position that was established last month to improve coordination among the army, navy and air force.

Munir has risen to prominence since earlier this year, when Pakistan said it defeated India in a four-day conflict. Chaudhry said Khan is deliberately trying to stoke hostility toward the military.

“We will not allow anyone to create rifts between Pakistan’s military and its people,” Chaudhry said. He said the constitution guarantees freedom of expression but also places limits and does not allow anyone to undermine national security. Chaudhry linked Khan to the May 9, 2023, attacks on military installations, including the army’s headquarters in Rawalpindi.

“Was it not this same individual who orchestrated those attacks?” he said.

The 2023 violence erupted after Khan’s arrest, when thousands of his supporters stormed government and military facilities. Khan has pleaded not guilty to charges of inciting the unrest.

Chaudhry said it was up to the civilian government — not the military — to decide whether Khan’s party should be banned. He described the former prime minister’s alleged anti-army messaging a national security concern and claimed it operated “in deep collusion with external actors.”

Khan was ousted in a no-confidence vote in April 2022. His party now sits in opposition and continues to allege that the 2024 parliamentary elections were rigged to favor current premier Sharif, a claim the government denies.

Supporters of Pakistan's imprisoned former Prime Minister Imran Khan hold a demonstration outside Islamabad High Court, in Islamabad, Pakistan, Tuesday, Dec. 2, 2025. (AP Photo/A. Sheikh)